API | dexpramipexole

dexpramipexole Report issue

Small molecule Experimental

AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW

Dexpramipexole (KNS-760704) is an orally administered drug candidate shown to selectively and significantly lower eosinophil counts in human blood and tissue. The drug is currently in clinical development for eosinophil-associated diseases by Knopp Biosciences LLC. ^Wikipedia

Chemistry

SMILES: CCCN[C@@H]1CCc2nc(N)sc2C1
InChIKey: FASDKYOPVNHBLU-SSDOTTSWSA-N
Mol. Mass: 211.33
ALogP: 1.58 Partition coefficient
ChEMBL Molecules:

dexpramipexole

dexpramipexole dihydrochloride

More Chemistry

Pharmacology

Mechanisms of Action: Missing data
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

dexpramipexole | dexpramipexole dihydrochloride | dexprampexole

Organizations (3)

Research & Development (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (6)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (6)

Amyotrophic Lateral Sclerosis (Phase 3)

Asthma (Phase 2)

Healthy Volunteers (Phase 1)

Hypereosinophilic Syndrome (Phase 2)

Renal Insufficiency (Phase 1)

Sinusitis (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 12
# of Trial Organizations: 3

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue